Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20097982 | 0.88 | TSHR (0.39) | TSHRTTRALBKMT2AMEN1 | |
| SCHEMBL28309196 | 0.83 | TSHR (0.39) | TSHRTTRALBKMT2AMEN1 | |
| SCHEMBL30394200 | 0.81 | TSHR (0.50) | TSHRKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL21763267 | 0.81 | TTR (0.42) | TSHRTTRALBXDHDYRK1A | |
| SCHEMBL8954330 | 0.81 | TSHR (0.50) | TSHRKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL17679790 | 0.80 | TSHR (0.41) | TSHRTTRALBKMT2AALDH1A1 | |
| SCHEMBL12082090 | 0.79 | AR (0.43) | KMT2AALDH1A1 | |
| SCHEMBL21212728 | 0.78 | TTR (0.40) | TSHRTTRALBXDHDYRK1A | |
| SCHEMBL4203403 | 0.76 | TSHR (0.46) | TSHRKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL119203 | 0.75 | TSHR (0.50) | TSHRKMT2AMEN1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842939-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-2842939-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| EP-2842946-B1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2842946-B1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2842946-A1 | QUINAZOLINEDIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-2842946-A1 | QUINAZOLINEDIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-2842939-A1 | BENZAMIDE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-2842939-A1 | BENZAMIDE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| WO-2013161853-A1 | QUINAZOLINEDIONE DERIVATIVE | 中外製薬株式会社 (JP) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013161851-A1 | BENZAMIDE DERIVATIVE | 中外製薬株式会社 (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2011085039-A2 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | EP300, HDAC1, KAT2A | TSHR 3344/4885TTR 4522/4885ALB 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.